Publication date: Available online 6 February 2018
Source:Bioorganic & Medicinal Chemistry
Author(s): Hongwu Liu, Jianwei Wu, Ying Ge, Aibo Li, Jia Li, Zhengshi Liu, Yungen Xu, Qingxiang Xu, Yuyan Li
A novel series of non-peptide proteasome inhibitors (PIs) that act on chymotrypsin-like (ChT-L) of the proteasome were developed. These PIs bearing 4-aromatic sulfonyl naphthalene-based scaffold and Leu-boronic moiety as covalent bonding group displayed far better activity than PI-8182 for inhibiting ChT-L in preliminary biological activity test. The results showed that 2a (IC50 = 6.942 μM, MCF-7) and 2c (IC50 = 6.905 μM, MCF-7) displayed higher anti-proliferative activities than Bortezomib (IC50 = 18.37 μM, MCF-7) under our experimental conditions. Furthermore, in the microsomal stability assay, 2a demonstrated excellent metabolic stability profiles with 56% remaining after 40 min, as compared to Bortezomib of which approximately 30% was remaining. The compounds 2a, 2c emerged as promising lead compounds for the development of novel non-peptide boronate PIs.
Graphical abstract
http://ift.tt/2nQ9tvU
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου